Iván Sánchez-Sánchez

Iván Sánchez-Sánchez

Auto-generated profile, based on publicly available information

Iván Sánchez-Sánchez

Cardiology Department, Instituto Cardiovascular, Hospital Clinico San Carlos, IdISSC, Madrid, Spain (L.N.-F., I.S.).

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2024 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
ISIván Sánchez-Sánchez
Iván Sánchez-Sánchez
ECEnrico Cerrato
Enrico Cerrato
MBMario Bollati
Mario Bollati
CECarolina Espejo
Carolina Espejo
LNLuis Nombela
Luis Nombela
INIván J. Núñez-Gil
Iván J. Núñez-Gil

1 October 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
ATAntonin Trimaille
Antonin Trimaille
PCPedro Luis Cepas-Guillen
Pedro Luis Cepas-Guillen
MUMarina Urena
Marina Urena
AAAlberto Alperi
Alberto Alperi
GVGabriela Veiga-Fernandez
Gabriela Veiga-Fernandez
JRJosep Rodés-Cabau
Josep Rodés-Cabau
BACKGROUND: Data on the long-term incidence and clinical impact of bioprosthetic valve failure (BVF) after transcatheter aortic valve replacement remain limited. This study aimed to assess the incidence, predictors, and clinical impact of BVF following transcatheter aortic valve replacement. METHODS: We analyzed data from an international, multicenter registry including consecutive patients undergoing transcatheter aortic valve replacement at 13 centers. The primary outcome was BVF according to Valve Academic Research Consortium-3 criteria. The cumulative incidence of BVF was estimated using a competing-risk approach. The association between BVF and clinical outcomes was assessed using competing-risk models with BVF as a time-dependent covariate. RESULTS: Among 7501 patients, BVF occurred in 380 (5.1%) patients over a median follow-up of 4 (interquartile range, 2–5) years. The cumulative incidence of BVF increased over time, reaching 1.4% at 1 year, 4.6% at 5 years, and 8.3% at 10 years. Independent predictors of BVF included younger age, smoking, balloon-expandable valve, prosthesis size <26 mm, valve-in-valve procedure, mean gradient at discharge ≥15 mm Hg, moderate or severe aortic regurgitation at discharge, and early hemodynamic valve deterioration. BVF was independently associated with an increased risk of all-cause mortality (adjusted hazard ratio, 1.72 [95% CI, 1.47–2.01]; P <0.001), cardiovascular mortality (adjusted hazard ratio, 3.23 [95% CI, 2.73–3.82]; P <0.001), stroke (adjusted hazard ratio, 2.08 [95% CI, 1.08–4.23]; P =0.043), and heart failure hospitalization (adjusted hazard ratio, 1.43 [95% CI, 1.03–1.98]; P =0.032). Consistent findings were observed in different sensitivity analyses. CONCLUSIONS: BVF is a clinically relevant event associated with adverse long-term outcomes. These findings support the implementation of tailored surveillance and preventive strategies to mitigate BVF-related risk.

18 November 2026 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
ISIván Sánchez-Sánchez
Iván Sánchez-Sánchez
COCarmen Olmos
Carmen Olmos
PZPablo Zulet
Pablo Zulet
IMIsabel Martins Moreira
Isabel Martins Moreira
SGSandra Gil-Abizanda
Sandra Gil-Abizanda
FIFabián Islas
Fabián Islas